Integrated Filing — IndAS


General information about company

Scrip Code 524558
NSE Symbol NEULANDLAB
MSEI Symbol NOTLISTED
ISIN INE794A01010
Name of company Neuland Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 15-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-Apr-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Manufacturing of Active Pharmaceuticals
Start date and time of board meeting 15-May-2025   14:00:00
End date and time of board meeting 15-May-2025   15:46:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion



Financial Results Ind-AS

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3283600000 14768373000
Other income 74643000 205093000
Total income 3358243000 14973466000
2 Expenses
(a) Cost of materials consumed 1412415000 5748068000
(b) Purchases of stock-in-trade 0 0
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -143414000 128312000
(d) Employee benefit expense 664575000 2720048000
(e) Finance costs 23467000 82971000
(f) Depreciation, depletion and amortisation expense 168919000 655466000
(f) Other Expenses
1 Manufacturing Expenses 450903000 1628700000
2 Other Expenses 388382000 1310647000
Total other expenses 839285000 2939347000
Total expenses 2965247000 12274212000
3 Total profit before exceptional items and tax 392996000 2699254000
4 Exceptional items 0 764036000
5 Total profit before tax 392996000 3463290000
6 Tax expense
7 Current tax 60233000 737668000
8 Deferred tax 54704000 124541000
9 Total tax expenses 114937000 862209000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 278059000 2601081000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 278059000 2601081000
17 Other comprehensive income net of taxes 2036000 -448000
18 Total Comprehensive Income for the period 280095000 2600633000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0 0
Total profit or loss, attributable to non-controlling interests 0 0
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0 0
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0 0
21 Details of equity share capital
Paid-up equity share capital 129005000 129005000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 15110669000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 21.67 202.74
Diluted earnings (loss) per share from continuing operations 21.67 202.74
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 21.67 202.74
Diluted earnings (loss) per share from continuing and discontinued operations 21.67 202.74
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results 1ThefinancialresultsforthequarterandyearendedMarch312025havebeenreviewedbytheAuditCommitteeandapprovedbytheBoardofDirectorsattheirmeetingheldonMay152025 n2ThefinancialresultshavebeenpreparedinaccordancewiththeIndianAccountingStandardsprescribedunderSection133oftheCompaniesAct2013andotheraccountingprinciplesgenerallyacceptedinIndiaandintermsofRegulation33oftheSEBIListingRegulations n3Theconsolidatedfinancialresultsincluderesultsofthefollowingwhollyownedsubsidiaries naNeulandLaboratoriesIncUSA nbNeulandLaboratoriesKKJapan n4TheoperationsoftheCompanyarepredominantlyrelatedtothemanufactureandsaleofactivepharmaceuticalingredientsandalliedservicesAssuchthereisonlyoneprimaryreportablesegmentasperIndAS108OperatingSegments n5DuringtheyeartheCompanyhasfullytransferredaninvestmentpropertylocatedinNanakramgudaHyderabadTelanganathroughperpetualleaseresultingintotalprofitofRs7640lakhsForthequarterendedJune302024Rs2062lakhsandforthequarterendedDecember312024Rs5578lakhsbeingtheprofitisexceptionalinnatureithasbeendisclosedasaseparatelineitem n6TheEPSforquartershasnotbeenannualised n7TheBoardofDirectorshasrecommendedadividendofRs12onlyperequityshareofRs10eachsubjecttoapprovalofshareholdersfortheyearendedMarch312025 n8ThefiguresforthequarterendedMarch312025andMarch312024arethebalancingfiguresbetweentheauditedfiguresinrespectofthefullfinancialyearandthepublishedunauditedfiguresuptoninemonthsoftherelevantfinancialyear n



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 6737135000
Capital work-in-progress 445529000
Investment property 0
Goodwill 2794610000
Other intangible assets 17432000
Intangible assets under development 31108000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 15289000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 93516000
Total non-current financial assets 108805000
Deferred tax assets (net) 113233000
Other non-current assets 155996000
Total non-current assets 10403848000
2 Current assets
Inventories 3857569000
Current financial asset
Current investments 1076827000
Trade receivables, current 3157205000
Cash and cash equivalents 1319304000
Bank balance other than cash and cash equivalents 1268886000
Loans, current 0
Other current financial assets 22156000
Total current financial assets 6844378000
Current tax assets (net) 0
Other current assets 693021000
Total current assets 11394968000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 21798816000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 129005000
Other equity 15119058000
Total equity attributable to owners of parent 15248063000
Non controlling interest 0
Total equity 15248063000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 907274000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 186176000
Total non-current financial liabilities 1093450000
Provisions, non-current 72223000
Deferred tax liabilities (net) 728221000
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 1893894000
Current liabilities
Current financial liabilities
Borrowings, current 452827000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 84304000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2437732000
Total Trade payable 2522036000
Other current financial liabilities 870569000
Total current financial liabilities 3845432000
Other current liabilities 789570000
Provisions, current 20972000
Current tax liabilities (Net) 885000
Deferred government grants, Current 0
Total current liabilities 4656859000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 6550753000
Total equity and liabilites 21798816000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain/(loss) on defined benefit plans -322000 -5630000
2 Equity instruments through other comprehensive income 2663000 2799000
Total Amount of items that will not be reclassified to profit and loss 2341000 -2831000
2 Income tax relating to items that will not be reclassified to profit or loss 590000 -712000
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences in translating the financial statements of foreign operations 285000 1671000
Total Amount of items that will be reclassified to profit and loss 285000 1671000
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 2036000 -448000



Cash flow statement, indirect

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 2024-04-01
B Date of end of reporting period 2025-03-31
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Consolidated
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3463290000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 82971000
Adjustments for decrease (increase) in inventories -353350000
Adjustments for decrease (increase) in trade receivables, current 549067000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets 83804000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 25300000
Adjustments for other financial assets, current -19048000
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 587567000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -62086000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 655466000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current -4892000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current -228513000
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -1895000
Adjustments for dividend income 0
Adjustments for interest income 105840000
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) -76827000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -673924000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 457800000
Net cash flows from (used in) operations 3921090000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 747262000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 3173828000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 11642000
Purchase of property, plant and equipment 2064640000
Proceeds from sales of investment property 954313000
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 92905000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -1975780000
Net cash flows from (used in) investing activities -2981560000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 947782000
Repayments of borrowings 394353000
Payments of lease liabilities 54173000
Dividends paid 179618000
Interest paid 70028000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 249610000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 441878000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 1671000
Net increase (decrease) in cash and cash equivalents 443549000
Cash and cash equivalents cash flow statement at beginning of period 875754000
Cash and cash equivalents cash flow statement at end of period 1319303000







Details of Impact of Audit Qualification

Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M/s M S K A & Associates Yes 31-Jul-2027


Financial details

Sr. Particulars Audited Figures (as reported before adjusting for qualifications) Adjusted Figures (audited figures after adjusting for qualifications)
1 Turnover / Total income
2 Total Expenditure
3 Net Profit/(Loss)
4 Earnings Per Share
5 Total Assets
6 Total Liabilities
7 Net Worth




Signatories detail

Name of CEO / Managing director
Name of CFO
Name of audit committee chairman
Name of statutory auditor
Name of other signatory, if any, with designation
Place
Date